Cathie Wood’s ARK Invest actively rotated out of large-cap technology, crypto-linked equities, and consumer internet names ...

Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His ...

The Fair's Video Art programme, 'Reading the Room', features a focused selection of regional and international moving-image works that trace the tensions between human intuition and algorithmic ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Abstract: Mathematics is filled with conjectures that involve infinite recursive structure, representing complex structures and underlying deep relationships. Discovering such conjectures is crucial ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio ...